Pragya Kumar

This study identifies SPHK2 as a therapeutic target in G3MB, showing that its inhibition restores anti-tumor immunity and improves survival in mouse models, with enhanced effects when combined with radiation.

This study shows that stromal niches protect lung cancers from ALK inhibitors through multiple mechanisms, and targeting these mechanisms together is more effective than targeting them individually.

This paper identifies CYP3A4 hyperactivation as a tumor-extrinsic resistance mechanism in NSCLC, showing it reduces drug exposure and leads to resistance, and proposes dosing optimization and CYP3A4 inhibition as solutions.